Literature DB >> 7569775

Binding to erythrocyte complement receptor type 1 of BSA/anti-BSA complexes opsonized by C4A3 or C4B1 in the presence of serum.

C Klint1, L Truedsson, G Sturfelt.   

Abstract

An in vitro model with human serum and human 0 Rh-negative erythrocytes was used for studies on preformed BSA/anti-BSA complex binding to complement receptor type 1 (CR1). The serum used was first depleted of Clq, factor D and properdin, then of C3, C4 or both and finally reconstituted with the desired proteins (serum reagent). With varying C4 concentrations and 100% C3 present, binding curves obtained for the two C4 isotypes were similar. When the serum reagent was not reconstituted with factor D and properdin there was no difference between the CR1 binding of normal serum and the partially reconstituted serum reagent, nor between the two C4 isotypes in this serum reagent. When C3 at 50% or 100% of normal concentrations was added to the serum reagent together with 100% C4A3 or C4B1, the C4B1-opsonized complexes showed more binding than the C4A3-opsonized complexes. At very low levels of C3 (< 25%) the binding could not be distinguished from the background. The results suggest that the binding of complement opsonized antigen/antibody complexes to erythrocyte CR1 is mediated mainly by C3, originating from activation of the classical pathway, and that the difference in properties between C4A and C4B does not have a major influence.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7569775     DOI: 10.1111/j.1365-3083.1995.tb03676.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  2 in total

1.  Quantitative analysis of C4Ab and C4Bb binding to the C3b/C4b receptor (CR1, CD35).

Authors:  B D Reilly; C Mold
Journal:  Clin Exp Immunol       Date:  1997-11       Impact factor: 4.330

2.  Complement classical pathway components are all important in clearance of apoptotic and secondary necrotic cells.

Authors:  B Gullstrand; U Mårtensson; G Sturfelt; A A Bengtsson; L Truedsson
Journal:  Clin Exp Immunol       Date:  2009-03-02       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.